Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Canadian (TSX) Pharma Industry Analysis

UpdatedMar 06, 2026
DataAggregated Company Financials
Companies58
  • 7D-6.2%
  • 3M-5.7%
  • 1Y19.3%
  • YTD-18.0%

Over the last 7 days, the Pharma industry has dropped 6.2%, driven by Curaleaf Holdings declining 8.7%. On the other hand Medexus Pharmaceuticals is actually up 9.7%. This takes the industry's 12 month performance to a gain of 19%. Looking forward, earnings are forecast to grow by 53% annually.

Industry Valuation and Performance

Has the Canadian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 06 Mar 2026CA$14.3bCA$11.3b-CA$1,802,457,547.5712.8x-7.9x1.3x
Sun, 01 Feb 2026CA$14.3bCA$11.2b-CA$1,970,176,869.8916.1x-7.2x1.3x
Tue, 30 Dec 2025CA$15.9bCA$11.2b-CA$1,937,564,464.5016x-8.2x1.4x
Thu, 27 Nov 2025CA$13.2bCA$11.4b-CA$1,924,539,780.5914.3x-6.9x1.2x
Sat, 25 Oct 2025CA$16.6bCA$11.3b-CA$2,039,568,629.5435.1x-8.1x1.5x
Mon, 22 Sep 2025CA$16.1bCA$11.2b-CA$2,028,829,168.5239.4x-7.9x1.4x
Wed, 20 Aug 2025CA$16.8bCA$11.9b-CA$2,556,798,331.4336.1x-6.6x1.4x
Fri, 18 Jul 2025CA$10.5bCA$11.8b-CA$2,550,526,609.1619.3x-4.1x0.9x
Sun, 15 Jun 2025CA$9.6bCA$11.6b-CA$2,503,258,167.2918.3x-3.8x0.8x
Tue, 13 May 2025CA$10.1bCA$12.0b-CA$2,544,512,910.5421.8x-4x0.8x
Thu, 10 Apr 2025CA$8.7bCA$12.2b-CA$2,605,684,898.2218.5x-3.3x0.7x
Sat, 08 Mar 2025CA$10.9bCA$12.3b-CA$2,628,309,078.4422.6x-4.2x0.9x
Mon, 03 Feb 2025CA$12.0bCA$12.3b-CA$2,397,744,121.5625.9x-5x1x
Wed, 01 Jan 2025CA$12.5bCA$12.1b-CA$2,412,094,442.2431.2x-5.2x1x
Fri, 29 Nov 2024CA$14.5bCA$11.9b-CA$2,564,658,870.6320.3x-5.7x1.2x
Sun, 27 Oct 2024CA$20.5bCA$11.8b-CA$2,719,008,808.5818.4x-7.5x1.7x
Tue, 24 Sep 2024CA$17.8bCA$11.6b-CA$2,695,385,273.3421.3x-6.6x1.5x
Thu, 22 Aug 2024CA$18.8bCA$11.6b-CA$2,739,448,317.0221.9x-6.9x1.6x
Sat, 20 Jul 2024CA$20.6bCA$11.7b-CA$3,194,939,376.4719.1x-6.4x1.8x
Mon, 17 Jun 2024CA$19.3bCA$11.8b-CA$2,769,898,710.4213.2x-7x1.6x
Wed, 15 May 2024CA$24.6bCA$11.9b-CA$3,389,737,011.6614.1x-7.3x2.1x
Fri, 12 Apr 2024CA$25.2bCA$12.0b-CA$3,494,215,878.969.3x-7.2x2.1x
Sun, 10 Mar 2024CA$19.8bCA$11.9b-CA$3,898,781,168.647.5x-5.1x1.7x
Tue, 06 Feb 2024CA$23.6bCA$12.0b-CA$5,882,851,195.6313x-4x2x
Thu, 04 Jan 2024CA$18.5bCA$12.3b-CA$6,732,920,444.009.6x-2.8x1.5x
Sat, 02 Dec 2023CA$17.8bCA$12.4b-CA$6,759,702,801.008.7x-2.6x1.4x
Mon, 30 Oct 2023CA$14.7bCA$12.5b-CA$7,380,501,790.0011x-2x1.2x
Wed, 27 Sep 2023CA$20.6bCA$13.0b-CA$7,894,368,737.0013.8x-2.6x1.6x
Fri, 25 Aug 2023CA$13.6bCA$13.1b-CA$8,067,817,650.0015.3x-1.7x1x
Sun, 23 Jul 2023CA$14.9bCA$13.2b-CA$9,710,771,146.0012.2x-1.5x1.1x
Tue, 20 Jun 2023CA$14.7bCA$13.2b-CA$9,393,441,978.0012.5x-1.6x1.1x
Thu, 18 May 2023CA$15.0bCA$13.3b-CA$10,440,545,077.0010x-1.4x1.1x
Sat, 15 Apr 2023CA$15.1bCA$13.2b-CA$9,929,698,822.0010x-1.5x1.1x
Mon, 13 Mar 2023CA$18.9bCA$13.9b-CA$10,628,254,814.008.7x-1.8x1.4x
Price to Earnings Ratio

-1.8x


Total Market Cap: CA$18.9bTotal Earnings: -CA$10,628,254,814.00Total Revenue: CA$13.9bTotal Market Cap vs Earnings and Revenue0%0%0%
Canadian Pharma Industry Price to Earnings3Y Average -5x202420252026
Current Industry PE
  • Investors are relatively neutral on the Canadian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 1.4x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 6.8% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the Canadian Healthcare industry?

CA Market-2.97%
Healthcare-2.86%
Pharma-6.20%
Pharma-6.20%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
MDP Medexus PharmaceuticalsCA$3.169.7%
+CA$9.0m		19.7%PS0.8x
RX BioSyentCA$15.501.5%
+CA$6.2m		41.8%PE20.6x
GSD Devonian Health GroupCA$13.7512.2%
+CA$4.1m		23.9%PS2.1x
DB Decibel CannabisCA$0.105.0%
+CA$2.9m		40.0%PE5.2x
BBM Blueberries MedicalCA$0.0233.3%
+CA$2.5m		100.0%PS23.9x

Latest News

OILS
CA$0.065
Nextleaf Solutions
7D
18.2%
1Y
0%
GTII
CA$8.55
Green Thumb Industries
7D
-5.0%
1Y
-13.2%
CURA
CA$3.04
Curaleaf Holdings
7D
-8.7%
1Y
102.7%

CURA: Domestic Stabilization And International Expansion Will Support Future Upside

Analysts have trimmed their price target on Curaleaf Holdings to CA$5.50 from CA$6.00, citing a recent slight Q4 sales beat, efforts to stabilize the domestic business, and ongoing international growth opportunities. Analyst Commentary Bullish analysts trimmed their Curaleaf price target to CA$5.50 from CA$6.00, but are still framing the move as a recalibration rather than a negative call.
MDP
CA$3.16
Medexus Pharmaceuticals
7D
9.7%
1Y
19.7%
RX
CA$15.50
BioSyent
7D
1.5%
1Y
41.8%
TRUL
CA$8.31
Trulieve Cannabis
7D
-7.2%
1Y
40.6%
CL
CA$1.26
Cresco Labs
7D
-8.0%
1Y
21.2%
CRON
CA$3.52
Cronos Group
7D
-4.1%
1Y
23.1%

CRON: Canadian Brand Strength And Rescheduling Shift Will Reshape Risk Reward Profile

Analysts have lifted their fair value estimate for Cronos Group to CA$4.24 from CA$3.95, pointing to higher assumed revenue growth and a lower future P/E multiple. They are factoring in recent bullish coverage highlighting the company’s established Canadian cannabis brands, lean cost base, and cultivation practices.
WEED
CA$1.43
Canopy Growth
7D
-8.3%
1Y
-14.4%

WEED: Term Loan And Equity Raise Will Support Future Portfolio Expansion

Analysts have adjusted their price target on Canopy Growth to CA$5.00, reflecting updated assumptions for revenue growth, profit margins, and a slightly lower future P/E multiple. What's in the News Filed a follow-on equity offering of approximately $19.27 million, covering 18,705,578 common shares priced at about $1.03 per share (Key Developments).
VRNO
CA$1.44
Verano Holdings
7D
-5.3%
1Y
44.0%

VRNO: Expanding Retail Footprint And New License Will Drive Future Upside

Analysts have made a modest adjustment to their CA$ price target on Verano Holdings, reflecting updated assumptions about discount rates, revenue growth, profit margins and future P/E multiples. They are now presenting the stock’s outlook with a more refined view of its risk and earnings profile.
GSD
CA$13.75
Devonian Health Group
7D
12.2%
1Y
23.9%
VREO
CA$0.56
Vireo Growth
7D
-13.8%
1Y
30.2%
DB
CA$0.10
Decibel Cannabis
7D
5.0%
1Y
40.0%

Is Decibel Cannabis (CVE:DB) Using Debt In A Risky Way?

Jan 23
Is Decibel Cannabis (CVE:DB) Using Debt In A Risky Way?
BBM
CA$0.02
Blueberries Medical
7D
33.3%
1Y
100.0%
RVV
CA$0.02
Revive Therapeutics
7D
33.3%
1Y
300.0%
AYUR
CA$0.01
Ayurcann Holdings
7D
100.0%
1Y
-66.7%